Cambridge's Editas asks FDA to start gene editing trial
November 07, 2018 at 19:46 PM EST
Editas Medicine could be the next to test the widely watched gene editing technology CRISPR/Cas9 after filing a clinical trial application late last month, the company revealed Wednesday.